Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 7Unknown 5Not yet recruiting 3Terminated 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 2Gynecologic 2Other solid neoplasm 1Genitourinary 1

Conditions

Uterine Cervical Neoplasms 2Liver Neoplasms 1Esophageal Squamous Cell Carcinoma 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × toripalimab × Gynecologic × Clear all
NCT04651127 2026-03-10

Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

Sun Yat-sen University

Phase 1/2 Terminated
5 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT05427396 2025-12-03

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Terminated
31 enrolled
GastrointestinalGynecologic

Esophageal Squamous Cell Carcinoma, Uterine Cervical Neoplasms, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡